Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Five Prime and bluebird bio team up to develop new CART therapies

Executive Summary

Five Prime Therapeutics Inc. granted bluebird bio Inc. exclusive rights to antibodies against an undisclosed target, which bluebird will develop into chimeric antigen receptor T-cell (CART) therapies for solid and blood cancers.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register